Both treatments come with their own set of dangers, and its essential to weigh the side effects against the potential benefits before beginning a weight loss plan
The obesity and type 2 diabetes mellitus epidemics have prompted expanded use of incretin-based therapies
Single-cell, omics studies of human L-cells, which secrete GLP-1 and 2, may uncover regulatory networks controlling incretin secretion
Who should not take the Wegovy pill: It is not suitable for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2, people with a history of pancreatitis or serious kidney problems, or anyone who is pregnant, planning pregnancy, or breastfeeding
Continuing to eat the same number of calories that produced weight loss at 230 pounds will eventually stop producing results at 195 pounds